Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 1 2Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 1Disease Progression 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 79Cyclophosphamide 55Specimen Handling 54Carboplatin 50fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Biopsy 38Gemcitabine 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Pemetrexed 24Cisplatin 24Ipilimumab 23Capecitabine 21Temozolomide 19Fulvestrant 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Cetuximab 18Azacitidine 18Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × neratinib × 90 days × Clear all
NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Virginia Commonwealth University

Phase 1/2 Recruiting
83 enrolled
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT03377387 2026-04-16

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
34 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡